Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma. [PDF]
Hofstad M +3 more
europepmc +1 more source
Adverse Event Profiling and Comparative Analysis of HER2-targeting Antibody-drug Conjugates Using Pharmacovigilance Databases. [PDF]
Hosonaka K +5 more
europepmc +1 more source
Near-Infrared Organic Structures with Extended Lifetimes to Unlock the Potential of <i>In Vivo</i> Fluorescence Lifetime Imaging. [PDF]
Chazeau E +15 more
europepmc +1 more source
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer. [PDF]
Aoyama Y +15 more
europepmc +1 more source
A case report of pathological complete response in an elderly patient with advanced urothelial carcinoma treated with disitamab vedotin plus toripalimab. [PDF]
Songlin L +4 more
europepmc +1 more source
Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series. [PDF]
Di Lorenzo G +5 more
europepmc +1 more source

